Table 3 Cause of mortality in patients with IPF treated with antifibrotic therapy.

From: Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis

 

IPF combined cohort (n = 229)

Hamamatsu cohort (n = 110)

Seirei cohort (n = 119)

p-value (Hamamatsu cohort vs Seirei cohort)

Chronic respiratory failure

70 (57.4%)

33 (57.9%)

37 (56.9%)

1.0000

Acute exacerbation

29 (23.8%)

15 (26.3%)

14 (21.5%)

0.6704

Lung cancer

7 (5.7%)

2 (3.5%)

5 (7.7%)

0.4467

Pneumothorax

5 (4.1%)

4 (7.0%)

1 (1.5%)

0.1839

Infection

3 (2.5%)

1 (1.8%)

2 (3.1%)

1.0000

Others

8 (6.6%)

2 (3.5%)

6 (9.2%)

0.2813

Back to article page